Biodefense/Emerging Infection Vaccine Studies

生物防御/新发感染疫苗研究

• 批准号: 7732758
• 负责人: Barney Scott Graham
• 金额: $ 96.93万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7732758
• 关键词: Adenovirus Vector; Adult; Africa; Antibodies; Antibody Formation; Ascaridil; Avian Influenza; Avian Influenza A Virus; Bird Flu vaccine; Clinical Trials; Collaborations; Communicable Diseases; DNA; DNA Vaccines; Data; Devices; Dose; Ebola Vaccines; Ebola virus; Eligibility Determination; Evaluation; Filovirus; Frankfurt-Marburg Syndrome Virus; Future; Glycoproteins; Goals; H5 hemagglutinin; HIV; Human; Individual; Indonesia; Infection; Influenza; Influenza A Virus, H5N1 Subtype; Injection of therapeutic agent; Intramuscular; Learning; Military Personnel; Mission; Needles; Phase; Phase I Clinical Trials; Proteins; Publishing; Range; Recombinants; Recruitment Activity; Research; Route; Safety; Schedule; Series; Serotyping; Severe Acute Respiratory Syndrome; Syringes; T-Lymphocyte; Vaccines; West Nile virus; base; biodefense; defective adenoviral vector; design; dosage; immunogenicity; improved; influenza virus vaccine; influenzavirus; pathogen; pre-clinical; preclinical study; prevent; programs; research study; response; vector vaccine; viral DNA

Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. The ongoing screening protocol, VRC 300, is designed to recruit and screen healthy, HIV-negative subjects for investigational studies of vaccines to prevent infectious diseases (other than HIV). In FY 08, this project included clinical trials of investigational vaccines against three infectious diseases: Ebola, avian influenza, and Marburg virus. In FY 09 a Phase I evaluation of the Marburg virus DNA vaccine is expected to be completed and a Phase I evaluation of an Ebola virus DNA vaccine to begin. The evaluation of a recombinant adenoviral vector serotype 5 Ebola vaccine (Ebola-rAd5) is nearing completion. Two Phase I stuides of an avian influenza (H5) DNA vaccine were completed; one study was to evaluate dosage (VRC 304) and the other was to evaluate intradermal administration (VRC 305). The VRC 303 clinical trial of an investigational West Nile vaccine trial analysis was completed. Published results from Phase I dose clinical trials have included an Ebola DNA vaccine study (VRC 204) Clin Vaccine Immunol, 2006. 13(11):1267-77; a West Nile virus DNA vaccine (VRC 302) study J Infect Dis, 2007. 196(12):1732-40, and a SARS DNA vaccine (VRC 301) study.

对该项目中的研究疫苗的评估是与生物反应和新兴病原体有关的VRC任务的一部分。正在进行的筛查方案VRC 300旨在招募和筛查健康的HIV阴性受试者，以进行疫苗的研究研究，以防止感染性疾病（HIV以外）。在08财年，该项目包括针对三种传染病的研究性疫苗的临床试验：埃博拉病毒，禽流感和马堡病毒。在09财年，预计将完成对Marburg病毒DNA疫苗的I期评估，并对埃博拉病毒DNA疫苗进行I期评估。重组腺病毒载体血清型5埃博拉疫苗（Ebola-Rad5）的评估接近完成。完成了禽流感（H5）DNA疫苗的两期Stuides；一项研究是评估剂量（VRC 304），另一项是评估皮内给药（VRC 305）。 VRC 303研究西尼罗河疫苗试验分析的临床试验完成了。 I期临床试验的发表结果包括一项埃博拉DNA疫苗研究（VRC 204）临床疫苗Immunol，2006。13（11）：1267-77；西尼罗河病毒DNA疫苗（VRC 302）研究J Infect Dis，2007。196（12）：1732-40和SARS DNA疫苗（VRC 301）研究。